The lncRNA SEMA3B-AS1/HMGB1/FBXW7 Axis Mediates the Peritoneal Metastasis of Gastric Cancer by Regulating BGN Protein Ubiquitination

Table 2

Univariate and multivariate analyses of clinicopathologic parameters correlated with progression-free survival (PFS) and overall survival (OS).

Parameters	Overall survival						Progression-free survival
	Univariate analysis			Multivariate analysis			Univariate analysis			Multivariate analysis
	HR	95% CI	value	HR	95% CI	value	HR	95% CI	value	HR	95% CI	value
Gender (male vs. female)	0.799	0.378-1.691	0.557				0.833	0.393-1.763	0.629
Age (≥60 years vs. <60 years)	0.708	0.327-1.532	0.381				0.709	0.328-1.533	0.382
Cancer grade (poor vs. moderate/well)	3.248	0.986-10.701	0.053				3.386	1.028-11.155	0.045	1.533	0.342-6.886	0.577
Cancer size (cm) (≥5 vs. <5)	1.781	0.834-3.801	0.136				1.752	0.821-3.738	0.147
T stage (T3-4 vs. T1-2)	2.845	0.988-8.192	0.053				2.935	1.020-8.455	0.046	1.519	0.184-12.522	0.698
Lymphatic metastasis (N2-3 vs. N0-1)	4.083	1.810-9.208	0.001	5.204	1.641-16.507	0.005	4.029	1.785-9.902	0.001	4.791	1.509-15.209	0.008
TNM stage (III/IVVSI/II)	3.713	1.501-9.185	0.005	0.522	0.091-3.343	0.518	3.758	1.520-9.293	0.004	0.513	0.085-3.087	0.466
CEA (ng/mL) (≥5 vs. <5)	1.601	0.687-3.732	0.275				1.625	0.697-3.786	0.261
CA19-9 (u/mL) (≥37 vs. <37)	2.927	1.319-6.495	0.008	2.191	0.635-7.553	0.214	2.769	1.244-6.164	0.013	1.531	0.431-5.435	0.51
SEMA3B-AS1 expression (high vs. low)	0.113	0.034-0.383	<0.001	0.113	0.021-0.603	0.011	0.112	0.033-0.376	<0.001	0.123	0.023-0.662	0.015
PM (no vs. yes)	0.245	0.111-0.539	<0.001	0.25	0.077-0.814	0.021	0.225	0.102-0.493	<0.001	0.193	0.061-0.615	0.005

Remark: tumor staging guidelines: AJCC Cancer Staging Manual (8th). Abbreviations: TNM: tumor-node-metastasis; CEA: carcinoembryonic antigen; CA19-9: carbohydrate antigen 19-9; T stage: tumor invasion stage; PM: peritoneal metastasis. : statistically significant.